GSK (LON:GSK) Insider Julie Brown Buys 8 Shares

Key Points

• Insider Julie Brown purchased 8 shares of GSK stock on September 9th for an average cost of GBX 1,486 per share, totaling £118.88.
• GSK shares traded down 0.3% to GBX 1,485.98, with a market cap of £59.85 billion and a PE ratio of 1,796.83.
• Analysts have mixed ratings on GSK, with one "Buy," two "Hold," and one "Sell" recommendation, and a consensus target price of GBX 1,637.50.

GSK plc (LON:GSK - Get Free Report) insider Julie Brown bought 8 shares of GSK stock in a transaction on Tuesday, September 9th. The shares were purchased at an average cost of GBX 1,486 per share, with a total value of £118.88.

Julie Brown also recently made the following trade(s):

• On Monday, August 11th, Julie Brown bought 9 shares of GSK stock. The shares were purchased at an average cost of GBX 1,408 per share, with a total value of £126.72.

GSK Trading Down 0.3%

Shares of GSK traded down GBX 5.02 during midday trading on Wednesday, reaching GBX 1,485.98. The company had a trading volume of 5,415,231 shares, compared to its average volume of 12,375,177. GSK plc has a 1-year low of GBX 1,242.50 and a 1-year high of GBX 1,675. The company has a quick ratio of 0.73, a current ratio of 0.81 and a debt-to-equity ratio of 114.64. The firm has a 50 day simple moving average of GBX 1,423.05 and a 200-day simple moving average of GBX 1,431.86. The stock has a market cap of £59.85 billion, a PE ratio of 1,796.83, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31.

GSK (LON:GSK - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The company reported GBX 75.30 earnings per share (EPS) for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. Research analysts forecast that GSK plc will post 175.980975 EPS for the current fiscal year.

Wall Street Analyst Weigh In

GSK has been the topic of a number of analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a GBX 1,450 target price on shares of GSK in a research note on Thursday, July 31st. JPMorgan Chase & Co. reduced their price target on shares of GSK from GBX 1,460 to GBX 1,400 and set an "underweight" rating on the stock in a research note on Monday, August 4th. Shore Capital reissued a "buy" rating and issued a GBX 2,100 price target on shares of GSK in a research note on Wednesday, August 27th. Finally, Berenberg Bank reissued a "hold" rating and issued a GBX 1,600 price target on shares of GSK in a research note on Friday, July 18th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of GBX 1,637.50.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.